17-18143622-G-C
Variant summary
Our verdict is Likely benign. Variant got -2 ACMG points: 2P and 4B. PM2BP4_Strong
The NM_016239.4(MYO15A):c.5964+3G>C variant causes a splice region, intron change involving the alteration of a non-conserved nucleotide. The variant allele was found at a frequency of 0.0000702 in 1,567,832 control chromosomes in the GnomAD database, with no homozygous occurrence. In-silico tool predicts a benign outcome for this variant. 3/3 splice prediction tools predict no significant impact on normal splicing. Variant has been reported in ClinVar as Conflicting classifications of pathogenicity (no stars).
Frequency
Consequence
NM_016239.4 splice_region, intron
Scores
Clinical Significance
Conservation
Genome browser will be placed here
ACMG classification
Verdict is Likely_benign. Variant got -2 ACMG points.
Transcripts
RefSeq
Ensembl
Frequencies
GnomAD3 genomes AF: 0.0000920 AC: 14AN: 152238Hom.: 0 Cov.: 33
GnomAD3 exomes AF: 0.0000344 AC: 6AN: 174324Hom.: 0 AF XY: 0.00 AC XY: 0AN XY: 93280
GnomAD4 exome AF: 0.0000678 AC: 96AN: 1415476Hom.: 0 Cov.: 38 AF XY: 0.0000629 AC XY: 44AN XY: 699816
GnomAD4 genome AF: 0.0000919 AC: 14AN: 152356Hom.: 0 Cov.: 33 AF XY: 0.0000537 AC XY: 4AN XY: 74504
ClinVar
Submissions by phenotype
not provided Uncertain:2
This sequence change falls in intron 26 of the MYO15A gene. It does not directly change the encoded amino acid sequence of the MYO15A protein. It affects a nucleotide within the consensus splice site. This variant is present in population databases (rs530975087, gnomAD 0.006%). This variant has not been reported in the literature in individuals affected with MYO15A-related conditions. ClinVar contains an entry for this variant (Variation ID: 179269). Variants that disrupt the consensus splice site are a relatively common cause of aberrant splicing (PMID: 17576681, 9536098). Algorithms developed to predict the effect of sequence changes on RNA splicing suggest that this variant may disrupt the consensus splice site. This variant disrupts the c.5964+3G nucleotide in the MYO15A gene. Other variant(s) that disrupt this nucleotide have been determined to be pathogenic (PMID: 24206587, 30953472). This suggests that this nucleotide is clinically significant, and that variants that disrupt this position are likely to be disease-causing. In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. -
In-silico analysis, which includes splice predictors and evolutionary conservation, is inconclusive as to whether the variant alters gene splicing. In the absence of RNA/functional studies, the actual effect of this sequence change is unknown. -
Autosomal recessive nonsyndromic hearing loss 3 Pathogenic:1
- -
not specified Uncertain:1
Variant classified as Uncertain Significance - Favor Benign. The 5964+3G>C varia nt in MYO15A has not been reported in individuals with hearing loss, and frequen cy data from large population studies is insufficient. This variant is located in the 5' splice region but not in the invariant +1/+2 positions in the splice s ite consensus sequence. Computational tools do not suggest and impact to splicin g; however, this information is not predictive enough to rule out pathogenicity. In summary, the clinical significance of this variant cannot be determined with certainty; however based upon splice site computational data, we would lean tow ards a more likely benign role. -
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at